A Phase II Single Arm Adaptive Weight Loss Study in Women With Early Stage Breast Cancer
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Naltrexone/bupropion (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms A-NEW
- 11 Nov 2024 Status changed from active, no longer recruiting to completed.
- 29 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2026.
- 30 Mar 2023 Status changed from recruiting to active, no longer recruiting.